Atrium Therapeutics, Inc. (RNA) Fair Value 2026

RNA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.7 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-28, Atrium Therapeutics, Inc. (RNA) trades at $13.64. QOC: 3.7/10. Value Trap Risk: 0/100 (SAFE). 0/13 models active.

Key Facts

Ticker
RNA
Price
$13.64
Quality Score
3.7/10
Value Trap Risk
0/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 3.7/10 signals weak fundamentals

What Fair Value Does Each Model Give RNA?

0 Intrinsic Value Models vs. Current Price ($13.64)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Atrium Therapeutics, Inc. (RNA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Atrium Therapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About RNA?

0 of 13 models are currently active for RNA. See which stocks rank higher →

How Does RNA Rank in Biotechnology?

Among 625 Biotechnology stocks, RNA ranks #564 by Quality of Company score. CirclFi's QOC score of 3.7/10 evaluates 32 fundamental signals. A score of 3.7 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Atrium Therapeutics, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating RNA should weigh these sector-specific dynamics alongside our model-derived fair values.

Is RNA a Value Trap?

CirclFi's Value Trap algorithm assigns RNA a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Atrium Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Atrium Therapeutics, Inc. is rated at 3.7/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RNA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Atrium Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

KALAKALA BIO, Inc.QOC 3.7ALZNAlzamend Neuro, Inc.QOC 3.7PBLSParabilis Medicines, Inc.QOC 3.7HEPAHepion Pharmaceuticals, Inc.QOC 3.6BIVIBioVie Inc.QOC 3.7ODTXOdyssey Therapeutics, Inc.QOC 3.6CRSPCRISPR Therapeutics AGQOC 6.5ICUSeaStar Medical Holding CorporationQOC 5.3ERASErasca, Inc.QOC 4.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: KALA · ALZN · PBLS · HEPA · BIVI · ODTX · CRSP · ICU · ERAS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to RNA?

6 companies across all industries closest to RNA’s Quality of Company score of 3.7/10.

ODYYOdyssey Health, Inc.QOC 3.7LBSRLiberty Star Uranium & Metals Corp.QOC 3.7SDOTSadot Group Inc.QOC 3.7BRBIBRBI BR Partners S.A.QOC 3.7NICMNicola Mining Inc.QOC 3.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ODYY · LBSR · SDOT · BRBI · NICM · NVDA

Where Does RNA Sit in CirclFi's Biotechnology Rankings?

RNA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Atrium Therapeutics, Inc.’s Valuation?

What is Atrium Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Atrium Therapeutics, Inc. (RNA). The Quality of Company score is 3.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RNA overvalued or undervalued right now?

At $13.64, 0 of 0 active models suggest RNA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Atrium Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.7 mean for RNA?

Atrium Therapeutics, Inc.'s QOC of 3.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RNA?

CirclFi analyzes RNA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is RNA a value trap in 2026?

Atrium Therapeutics, Inc.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Atrium Therapeutics, Inc. (RNA) a Quality of Company score of 3.7/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/RNA/ · Methodology
Primary sources for this RNA valuation
  • Financial statements: Atrium Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0002093101) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RNA as of ; valuations recomputed .